GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
Frequently asked questions
What sector does Entero Therapeutics, Inc. (GRDX) operate in?
Entero Therapeutics, Inc. belongs to the Utilities sector and operates in the Biotechnology industry.
What is Entero Therapeutics, Inc. (GRDX) current stock price?
As of the latest data, Entero Therapeutics, Inc. stock price is $5.64, with a previous close of $5.55. Entero Therapeutics, Inc. gained $0.09 in the last trading session, representing a 1.62% increase.
What is Entero Therapeutics, Inc. (GRDX) current market capitalization?
Entero Therapeutics, Inc. market cap is approximately 40.22 million.
What is Entero Therapeutics, Inc. (GRDX) Earnings Per Share (EPS)?
The trailing EPS is -$5.95.
What is Entero Therapeutics, Inc. (GRDX) EBITDA?
Entero Therapeutics, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.46 million.
Does Entero Therapeutics, Inc. (GRDX) pay dividends?
No. Entero Therapeutics, Inc. does not pay a dividend.
When is Entero Therapeutics, Inc. (GRDX) next earnings report?
Entero Therapeutics, Inc. is expected to release its next earnings report on September 30, 2026.
What is Entero Therapeutics, Inc. (GRDX) beta (volatility) score?
Entero Therapeutics, Inc. has a beta of 1.539, suggesting it is more volatile than the market.